Weidmann, Klaus published the artcile2-[(2-Pyridylmethyl)sulfinyl]-1H-thieno[3,4-d]imidazoles. A novel class of gastric H+/K+-ATPase inhibitors, SDS of cas: 149489-32-7, the main research area is pyridylmethylsulfinylthienoimidazole preparation inhibitor ATPase; stomach acid secretion inhibitor pyridylmethylsulfinylthienoimidazole; gastric acid secretion inhibitor pyridylmethylsulfinylthienoimidazole.
2-[(2-Pyridylmethyl)sulfinyl]thienoimidazoles I (R = H, Me, Ac, Ph, MeO2C, 4-MeOC6H4; R1 = H, Me, MeO2C; R2 = H, Me, MeO, F, Cl, Br, fluoroalkoxy; R3 = H, Me, alkoxy, and substituted alkoxy, benzyloxy, and phenoxy; R4 = H, Me, MeO, F, Cl, Br) and II (R, R1 = H, MeO2C; R2 = H, MeO) were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase. The [3,4-d] isomers of the two possible thienoimidazole series were found to be potent inhibitors of gastric acid secretion in vitro and in vivo. Structure-activity relationships indicate that especially lipophilic alkoxy, benzyloxy, and phenoxy substituents with addnl. electron-demanding properties in the 4-position of the pyridine moiety combined with an unsubstituted thieno[3,4-d]imidazole lead to highly active compounds with a favorable chem. stability. Various substitution patterns in the thieno[3,4-d]imidazole moiety result in lower biol. activity. Saviprazle [HOE 731, I; R-R2 = R4 = H, R3 = F3C(CF2)2CH2O] was selected for further development and is currently undergoing clin. evaluation. Comprehensive pharmacol. studies indicate a pharmacodynamic profile different to omeprazole, the first H+/K+-ATPase blocker introduced on the market.
Journal of Medicinal Chemistry published new progress about Stomach. 149489-32-7 belongs to class pyridine-derivatives, name is 2-(Chloromethyl)-3-fluoropyridine, and the molecular formula is C6H5ClFN, SDS of cas: 149489-32-7.